rLAS-uPA-eGP was fusogenic in uPAR expressing canine J3T and human U87 glioma cells (Figure 3), and the starting dose (dose cohort 1; Figure 1) of rLAS-uPA administered to dogs was derived from the median tissue culture infective dose (TCID50) obtained from J3T canine glioma cell line experiments. This evidence concerns the gene PLAU and central nervous system cancer.